FDA advisers reassert case against approval of Biogen's Alzheimer's drug

One of the most important decisions in the history of the Food and Drug Administration is quickly approaching. By early June, the agency should have a verdict on whether to approve aducanumab, a potentially first-of-its-kind treatment for Alzheimer's disease that became a major source of hope and controversy over the last two years.